B. Riley Weighs in on Cellular Biomedicine Group Inc’s Q2 2018 Earnings (CBMG)

Cellular Biomedicine Group Inc (NASDAQ:CBMG) – Research analysts at B. Riley lowered their Q2 2018 EPS estimates for Cellular Biomedicine Group in a report released on Monday, May 21st. B. Riley analyst G. Zavoico now expects that the biotechnology company will post earnings of ($0.52) per share for the quarter, down from their previous estimate of ($0.47). B. Riley has a “Buy” rating and a $32.00 price objective on the stock. B. Riley also issued estimates for Cellular Biomedicine Group’s Q3 2018 earnings at ($0.54) EPS, Q4 2018 earnings at ($0.57) EPS, FY2018 earnings at ($2.14) EPS and FY2019 earnings at ($2.46) EPS.

CBMG has been the topic of several other reports. Maxim Group reissued a “hold” rating on shares of Cellular Biomedicine Group in a report on Tuesday, March 6th. Zacks Investment Research downgraded Cellular Biomedicine Group from a “hold” rating to a “sell” rating in a report on Wednesday. ValuEngine raised Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a report on Wednesday, April 4th. Finally, BidaskClub downgraded Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a report on Wednesday, May 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $25.00.

Shares of Cellular Biomedicine Group opened at $17.50 on Wednesday, according to MarketBeat.com. The company has a market capitalization of $308.67 million, a PE ratio of -9.83 and a beta of 3.48. Cellular Biomedicine Group has a one year low of $5.50 and a one year high of $22.75.

Cellular Biomedicine Group (NASDAQ:CBMG) last announced its earnings results on Monday, May 7th. The biotechnology company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.05). The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.10 million. Cellular Biomedicine Group had a negative return on equity of 45.67% and a negative net margin of 9,594.83%.

In related news, Director Wen Tao Liu sold 10,400 shares of the business’s stock in a transaction that occurred on Tuesday, April 10th. The shares were sold at an average price of $20.10, for a total value of $209,040.00. Following the completion of the transaction, the director now owns 223,476 shares in the company, valued at approximately $4,491,867.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.30% of the company’s stock.

A hedge fund recently bought a new stake in Cellular Biomedicine Group stock. Tibra Equities Europe Ltd bought a new stake in shares of Cellular Biomedicine Group Inc (NASDAQ:CBMG) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund bought 27,777 shares of the biotechnology company’s stock, valued at approximately $487,000. Tibra Equities Europe Ltd owned about 0.16% of Cellular Biomedicine Group as of its most recent filing with the SEC. 4.09% of the stock is owned by institutional investors and hedge funds.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.

Earnings History and Estimates for Cellular Biomedicine Group (NASDAQ:CBMG)

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply